ELN 1998 & 1997 ventures per Form 20
Following is from 1998 Form-20 from ELN web site. Sorry for the formatting as it comes from a .pdf file. Apparently after this ELN stopped disclosing this info for "commercial" reasons - MFM
The following are the principal strategic collaborations established in 1998 and the principal additional
investments in pre-existing collaborations during 1998, including the amounts invested by Elan, the product or
technology licensed and the license fees received by Elan:
Company
Amount
Invested Product/Technology
License
Fee
Received
Multiple Peptide Systems, Inc.(1) $17.0 million Licensed technology relating to delivery
of protein and peptide therapeutics
$15.0 million
MPS Newco Ltd. $3.0 million
Ligand(2) $65.0 million Licensed US and Canadian Morphelan rights $15.0 million
Iomai Corporation(3)
Xairo Corporation
$8.5 million
$2.0 million
Licensed technology relating to
transdermal delivery of vaccines
$10.0 million
Endorex Corporation(4)
Endorex Newco Ltd.
$8.4 million
$2.1 million
Licensed Medipad technology for delivery of
certain compounds
$10.0 million
Electropharmacology, Inc.(5) $8.1 million Licensed iontophoretic technology for
local delivery of drugs
$7.5 million
Sheffield Pharmaceuticals, Inc.(6) $18.5 million Licensed technology relating to pulmonary
delivery of drugs
$12.5 million
Delsys Pharmaceutical
Corporation(7)
$12.0 million Licensed certain oral drug delivery technology $15.0 million
Tackson Ltd. $6.0 million
RTP Pharma, Inc.(8)
Cyclosporine Therapeutics Ltd.
$19.6 million
$1.3 million
Licensed technology relating to delivery of
certain compounds
$12.5 million
Acorda Therapeutics, Inc.(9)
MS Research &
Development Corporation
$12.0 million
$3.0 million
Licensed rights to fampridine for treatment of
multiple sclerosis
$15.0 million
Emisphere Technologies, Inc.(10)
Ebbisham Limited
$4.1 million
$5.0 million
Joint venture with Emisphere Technologies,
Inc. to develop oral formulations of heparin
N/A
(1) Multiple Peptide Systems, Inc. specializes in the custom synthesis of peptides and the development of compounds
using combinatorial libraries.
(2) Ligand discovers, develops and markets new drugs in several areas including cancer, skin diseases, hormone-related
diseases, osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases.
(3) Iomai Corporation is developing a number of proprietary delivery technologies for the transdermal delivery of
vaccines.
(4) Endorex Corporation is a drug delivery and cancer products company.
(5) Electropharmacology, Inc. is a biotechnology company which is developing drug delivery and drug design
technologies.
(6) Sheffield Pharmaceuticals, Inc., is developing a number of pulmonary delivery technologies over a range of
therapeutic areas.
(7) Delsys Pharmaceutical Corporation is developing a novel manufacturing technology, and has established
collaborations with several companies, including Warner-Lambert Company, SmithKline Beecham, plc, and Glaxo
Wellcome, plc.
(8) RTP Pharma, Inc. develops novel formulations of drugs that are insoluble or poorly water-soluble.
(9) Acorda Therapeutics, Inc. specializes in the development of drugs for the treatment of central nervous system
diseases. The terms of the original agreement provided for Elan to appoint a director to the board of MS Research and
Development Corporation and members to a joint management committee. These terms were revised and such
appointments were not made. The impact of this revision is that Elan accounts for MS Research and Development
Corporation using the cost method.
(10) Emisphere Technologies, Inc. is developing drug delivery systems for the oral delivery of macromolecules and other
compounds. Elan previously invested $4.5 million in Ebbisham Limited and $9.2 million in Emisphere Technologies,
Inc.
16
The following are the principal strategic collaborations established in 1997, including the amount invested
by Elan, the product or technology licensed and the license fees received by Elan.
Company
Amount
Invested Product/Technology
License
Fee
Received
Endorex Corporation(1)
Innovax Corporation
$10.0 million
$2.0 million
Licensed technology relating to oral and mucosal delivery of
vaccines
$10.0 million
Bioject Medical
Technologies, Inc.(2)
$15.0 million Licensed technology relating to an ambulatory glucose
monitoring system
$15.0 million
Marathon Medical
Technologies, Inc. $3.0 million
RTP Pharma Inc.(3) $12.5 million Licensed technology relating to cyclosporine $7.5 million
Cytogen Corporation(4) $10.0 million Licensed rights to a once-daily morphine product. $7.5 million
Targon Corporation
IOMED, Inc.(5) $15.0 million Licensed iontophoretic technology for systemic
delivery of drugs
$15.0 million
(1) Endorex Corporation is a drug delivery and cancer products company.
(2) Bioject Medical Technologies, Inc. develops, manufactures and markets jet injection systems for
needle-free injections.
(3) RTP Pharma, Inc. develops novel formulations of drugs that are insoluble or poorly water-soluble.
(4) Cytogen Corporation develops and commercializes diagnostic and therapeutic products for cancer and
urological diseases. Elan acquired Targon Corporation in 1998.
(5) IOMED, Inc. develops and manufactures iontophoretic drug delivery systems.
Ligand Pharmaceuticals Incorporated: In September 1998, Elan and Ligand entered into a strategic
collaboration. Ligand discovers, develops and markets new drugs in the areas of cancer, skin diseases,
hormone-related diseases, osteoporosis, metabolic disorders and cardiovascular and inflammatory diseases.
Elan agreed to:
œ purchase $20.0 million of Ligand common stock;
œ purchase up to $110.0 million in issue price of Ligandfs zero coupon convertible senior notes due
2008, which are convertible into Ligand common stock; and
œ enter into a license agreement providing for a license to Ligand in the US and Canada of Elanfs
proprietary product Morphelan for the oncology and HIV markets. Morphelan, a once-daily solid oral
dosage form of morphine, is currently in Phase III clinical trials. |
